Tags: M&A, immunology, atopic dermatitis, asthma, long-acting biologics, IL-13

AbbVie to acquire Apogee, staking nearly $11B on long-acting autoimmune drugs

By FieldPulse Editorial · June 22, 2026

AbbVie's proposed Apogee acquisition adds a long-acting IL-13 contender that could eventually challenge Dupixent and deepen AbbVie's post-Humira immunology strategy.

AbbVie is updating, not inventing, its immunology growth story.

The proposed Apogee acquisition adds zumilokibart, a long-acting IL-13 antibody that could eventually give AbbVie a more direct role in atopic dermatitis and asthma, two markets where Dupixent has set the commercial pace.

The deal is large enough to matter now, even though the lead asset remains in development and no field team is preparing for an immediate launch.

BioPharma Dive reported that AbbVie will pay about $135.11 per share, a roughly 49% premium to Apogee's prior close, valuing the transaction at nearly $11 billion.

If completed, it would be AbbVie's largest acquisition since Allergan in 2019 and another sign that the company still sees immunology as the core arena where scale, differentiation, and commercial muscle matter most.

That matters for FieldPulse because AbbVie is no longer just defending legacy Humira erosion.

It is trying to shape what the next wave of inflammatory-disease competition will look like and which company gets to define the convenience standard in inflammatory care.

The commercial hook is dosing convenience.

BioPharma Dive said zumilokibart is being developed for anywhere from two to four injections per year, versus Dupixent's every-two-weeks schedule.

The asset also targets IL-13 directly rather than the broader receptor pathway used by Dupixent.

In Phase 2 testing, about two-thirds of treatment recipients reportedly achieved significant skin clearance after 16 weeks, along with notable improvement in itching.

AbbVie also highlighted a safety profile consistent with similar drugs and expects Phase 3 work to start later this year.

For AbbVie teams that already work through the post-Humira transition with Skyrizi and Rinvoq, the acquisition points to another push to deepen the company's immunology footprint rather than defend only its existing franchises.

For Sanofi and Regeneron teams, this is one of the clearest signs yet that large competitors still see room to challe.